Pressure BioSciences
Awarded
First
U.S.
Patent
for
Revolutionary Ultra Shear Technology
Platform
Patented
UST Platform,
with Unique Ability to Prepare High Quality Commercial Scale
Nanoemulsions,
Expected to
Significantly
Impact
PBI's
Growth and Profitability in 2021
South
Easton,
MA,
November
11,
2020
-- InvestorsHub NewsWire --
Pressure
BioSciences, Inc. (OTCQB:
PBIO) ("PBI" or the
"Company"),
a leader in the development and sale of broadly enabling,
pressure-based instruments,
consumables,
and platform solutions to
the worldwide life
sciences
and
other industries,
today
announced the
award
of
the
first
U.S.
patent for
its revolutionary Ultra Shear Technology™ (UST™) platform
entitled
"System
for High Pressure,
High Shear Processing of Fluids". This
new patent (US
10,823,159)
brings the Company's Intellectual Property ("IP") estate to a total
of 26
issued
patents.
UST was
created to revolutionize the processing of immiscible liquids -
usually processed into macro/micro emulsions - into high
quality, highly
profitable nanoemulsions.
Emulsions
are mixtures of two or more liquids (e.g., oils in water)
that typically
cannot be
blended into each other without the addition of chemicals called
emulsifiers (e.g., surfactants). Emulsions are used in
thousands
of products in everyday
use, including food, medical products, pharmaceuticals,
nutraceuticals, cosmetics, industrial lubricants, and even cannabis
oil extracts (e.g., CBD). Scientific data
indicate
that improved absorption, higher bioavailability, greater
stability, lower surfactant levels, and other advantages
(such as
more reliable dosing control) are better achieved with
high
quality nanoemulsions.
Dr.
Edmund Y. Ting, Sr. Vice President of Engineering of PBI and the
inventor on this patent, said: "Nanoemulsions have long been shown
to exhibit improved absorption, higher bioavailability, and greater
stability, while often requiring lower levels of emulsifiers than
macro/micro emulsion products. Because of these significant
advantages, nanoemulsions are currently the focus of numerous
research efforts worldwide. However, cost-effective scale-up of
high quality nanoemulsion processing at a commercial level
continues to be quite challenging. Importantly, we believe
that PBI's innovative and now patented UST platform can provide the
key to commercial success for nanoemulsion products."
PBI's
first
UST-based processing system (the BaroShear K45) is
planned
for commercial release
in
the
second
quarter 2021.
As
previously disclosed, the Company has received
pre-orders
for 12 BaroShear
K45 systems:
deposits
on these orders
are
due in the first quarter 2021.
The
Company believes that
following
its release, the patented
UST
processing
platform
could
play
a
significant role in the creation and improvement of medical,
consumer, and industrial products through its unique
ability
to prepare highly stable, high quality, water soluble
nanoemulsions at
a
reasonable
cost, and
at
industrial
scale.
Dr.
Alexander M. Lazarev, Chief Science Officer of
PBI,
commented: "We
believe there are significant opportunities for room-temperature
stable, economically-scalable nanoemulsion products
worldwide. These include pharmaceuticals (such
as drugs and vaccines)
and premium
dairy and other high-volume food products (like
salad dressings),
as
well as cosmetics, nutraceuticals,
and industrial materials (such as paints, coatings, and
lubricants).
We believe that PBI's vast experience and expertise in harnessing
the power of high pressure, coupled with our new and growing UST
Platform IP estate, has positioned us to be uniquely qualified to
lead in this much-needed and important new area of
commercially-viable nanoemulsification processing
that
blends otherwise immiscible fluids."
Mr.
Richard T. Schumacher, President and CEO of PBI,
said:
"We
are accelerating discussions with U.S., Canadian, and other
companies, academic organizations, and government agencies that
have expressed a strong desire to collaborate with PBI and acquire
access to our patented UST platform.
We are on course to establish collaborative development projects
with several of these companies and research groups addressing
different product and market opportunities. These programs should
lead to revenue-generating products in 2021. We believe there are
many industries that can benefit from UST-produced nanoemulsions
and that UST
will be an
area of rapid and sizeable growth for PBI moving
forward."
About
Pressure
BioSciences,
Inc.
Pressure
BioSciences,
Inc.
(OTCQB:
PBIO)
is
a
leader
in
the
development
and
sale
of
innovative,
broadly
enabling,
pressure-based
solutions
for
the
worldwide
life
sciences
and
other
industries.
Our
products
are
based
on
the
unique
properties
of
both
constant
(i.e.,
static)
and
alternating
(i.e.,
pressure
cycling
technology,
or
PCT)
hydrostatic
pressure.
PCT
is a
patented
enabling
technology
platform
that
uses
alternating
cycles
of hydrostatic
pressure
between
ambient
and
ultra-high
levels
to control
biomolecular
interactions
safely and reproducibly (e.g.,
cell
lysis,
biomolecule
extraction).
Our
primary
focus
is
in
the
development
of PCT-based
products
for
biomarker
and
target
discovery,
drug
design
and
development,
biotherapeutics
characterization
and
quality
control,
soil
&
plant
biology,
forensics,
and
counter-bioterror
applications.
Additionally,
major
new
market
opportunities
have
emerged
in
the
use
of
our
pressure-based
technologies
in
the
following
areas:
(1)
the
use
of our
recently
acquired,
patented
technology
from
BaroFold,
Inc.
(the
"BaroFold"
technology)
to
allow
entry
into
the
bio-pharma
contract
services
sector,
and
(2)
the
use
of our
recently-patented,
scalable,
high-efficiency,
pressure-based
Ultra
Shear
Technology
("UST")
platform
to
(i)
create
stable
nanoemulsions
of otherwise
immiscible
fluids
(e.g.,
oils
and
water)
and
to
(ii)
prepare
higher
quality,
homogenized,
extended
shelf-life
or room
temperature
stable
low-acid
liquid
foods
that
cannot
be
effectively
preserved
using
existing
non-thermal
technologies.
Forward
Looking
Statements
This
press
release
contains
forward-looking
statements.
These
statements
relate
to future
events
or
our
future
financial
performance
and
involve
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
or
our
industry's
actual
results,
levels
of
activity,
performance
or
achievements
to
be
materially
different
from
any
future
results,
levels
of activity,
performance
or
achievements
expressed,
implied
or inferred
by these
forward-looking
statements.
In some
cases,
you can
identify
forward-looking
statements
by
terminology
such
as
"may,"
"will,"
"should,"
"could,"
"would,"
"expects,"
"plans,"
"intends,"
"anticipates,"
"believes,"
estimates,"
"predicts,"
"projects,"
"potential"
or "continue"
or the
negative
of
such
terms
and
other
comparable
terminology.
These
statements
are
only
predictions
based
on
our
current
expectations
and projections
about
future
events.
You
should
not
place
undue
reliance
on
these
statements.
In evaluating
these
statements,
you
should
specifically
consider
various
factors.
Actual
events
or results
may
differ
materially.
These
and
other
factors
may cause
our actual
results
to
differ
materially
from
any
forward-looking
statement.
These
risks,
uncertainties,
and
other
factors
include,
but
are
not
limited
to,
the
risks
and
uncertainties
discussed
under
the
heading
"Risk
Factors"
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2019,
and
other
reports
filed
by
the
Company
from
time
to
time
with
the
SEC.
The
Company
undertakes
no
obligation
to
update
any
of the
information
included
in this
release,
except
as
otherwise
required
by law.
For more
information about PBI and this press release, please click on the
following website link:
http:/www.pressurebiosciences.com
Please
visit us on Facebook, LinkedIn, and Twitter.
Investor
Contacts:
Richard
T. Schumacher, President and
CEO (508)
230-1828 (T)
Alexander
V.
Lazarev,
Ph.D.,
Chief Science Officer (508)
230-1829 (F)
Edmund Y.
Ting, Sc.D., Sr. VP Engineering